Story

NovoCure Shares Surge Over 23% After JPMorgan Resumes Coverage

ENTHMSVIIDZHZH-TWJAKOHI
Jul 23, 20261 min read
NovoCure Shares Surge Over 23% After JPMorgan Resumes Coverage

Summary

Shares of oncology company NovoCure (NVCR) surged after JPMorgan resumed coverage, highlighting a day of significant, catalyst-driven moves in the U.S. market.

Text size
Background

Shares of NovoCure Limited (NVCR) surged 23.4% in trading to $19.33 after JPMorgan resumed coverage of the oncology-focused company. The move was a standout in a session characterized by significant, news-driven price swings across multiple sectors.

Analyst Action and Earnings Drive Gains

The primary catalyst for NovoCure's rally was JPMorgan's decision to resume coverage with a Neutral rating and a $17 price target, according to a report from Investing.com. The action prompted investor optimism about a potential turnaround for the company's cancer therapies.

Other companies also experienced sharp moves based on specific news. WEX Inc. (WEX) saw its stock climb 9.6% after the financial technology services provider posted a second-quarter earnings beat, raised its full-year guidance, and announced a new share buyback program.

Highlights from Broader Markets

A number of other stocks posted double-digit gains, indicating a broader search for momentum among traders. Key movers included:

Sample IUX Markets – In-articleAd
  • Cleveland-Cliffs Inc. (CLF): Rose 20.5% to $11.39.
  • Allegion plc (ALLE): Gained 12.5% to $157.40.
  • Lockheed Martin Corporation (LMT): Climbed 10.8% to $570.00.

Market Context and Investor Takeaways

Trading volumes for the day's top-moving stocks were reportedly well above their three-month averages, a signal of heightened institutional investor activity. The price action also suggests sector rotation, with capital flowing into biotechnology, defense, and specialty finance.

While some companies saw significant rallies, analyst ratings indicate potential for volatility. The source material noted that some stocks, such as Oceaneering International (OII), hit 52-week highs but had analyst price targets suggesting they were trading above their perceived fair value.

Read next

More on Stocks
Back to latest news

LATEST